Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > ACE inhibitor protects against cardiotoxicity
  • News

ACE inhibitor protects against cardiotoxicity

  • 18 June 2021
  • Janet Fricker
ACE inhibitor protects against cardiotoxicity
Total
0
Shares
0
0
0
0
0

In HER2 breast cancer, concurrent use of the ACE inhibitor lisinopril with trastuzumab-anthracyclines benefits left ventricular ejection fraction (LVEF). The study, abstract 509, presented in a poster session at the ASCO meeting, June 4-8, found breast cancer patients treated with trastuzumab plus anthracyclines experienced greater LVEF adverse effects than those using trastuzumab alone.

Trastuzumab has been shown to be highly effective for treating HER2-postive breast cancer, comprising around 30% of all breast cancers. However, trastuzumab has also been associated with declines in LVEF, and diagnosis of clinical heart failure prompts interruption and discontinuation of treatment. In cardiology, angiotensin-converting enzyme (ACE) inhibitors and beta blockers are widely used to both prevent and treat heart failure. Several studies have demonstrated favourable effects of ACE inhibitors and beta blockers in the prevention of chemotherapy induced toxicity.

For the current study, Pamela Munster, a medical oncologist from the University of California, San Francisco, and colleagues, evaluated the preventive impact of the ACE inhibitor lisinopril and the beta blocker carvedilol on LVEF during trastuzumab and anthracycline treatment.
In the prospective randomised study, 468 women with early stage HER2 positive breast cancer undergoing neoadjuvant chemotherapy with trastuzumab were randomised to receive once daily lisinopril (10mg), carvedilol (10g) or placebo during one year of treatment. The patients, mean age 51 years, were further stratified according to anthracycline use (AC+T) versus non-anthracycline use (nonAC+T). Patients were recruited from 127 community-based oncology practices. Overall, in the AC+T group there were 188 women, of whom 65 received lisinopril, 61 carvedilol and 62 placebo. In the non-AC+T group there were 276 women, of whom 91 received lisinopril, 95 carvedilol, and 90 placebo.

Results show rates of LVEF decline to <50% occurred in 21% for patients treated with an anthracycline + trastuzumab (AC+T) vs 4.1% treated with trastuzumab alone (nonAC+T). In the AC+T group LVEF <50% occurred in 10.8% of those treated with lisinopril vs 30.5% treated with placebo (P=0.045). A smaller, but not significant benefit was seen for carvedilol.
The incidence of cardiotoxicity manifesting as LVEF decrease by ≥ 10% from normal was similar in both ACT+T and the nonAC+T arms, and unaffected by either lisinopril or carvedilol.
During trastuzumab therapy, a small but not clinically relevant decrease in LVEF was observed in all patients which was not significantly altered by either lisinopril or carvedilol. Lisinopril was shown to be tolerable even in patients without hypertension.

“In women treated in a community-based environment who will benefit from anthracyclines, or where anthracyclines are indicated, one should anticipate the decrease in left ventricular ejection fraction to below normal is larger than reported in other groups. However, this could be prevented by lisinopril,” concluded study presenter Pamela Munster.

The study, she added, suggests drops in LVEF to below 50%, which occurred in 21% (38) of patients taking anthracyclines, were much larger than previously reported.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • ACE inhibitor
  • beta blocker
  • cardiotoxicity
  • carvedilol
  • HER2 breast cancer
  • left ventricular ejection fraction
  • lisinopril
  • trastuzumab
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Advance Care Planning increases hope

  • 18 June 2021
  • Janet Fricker
View Post
Next Article
  • Articles
  • Medicine

Innovations in supportive care: cancer treatment side effects

  • 18 June 2021
  • Rachel Brazil
View Post
You May Also Like
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Janet Fricker
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • CancerWorld issue #103 (May, 2025)
    • 11 May 2025
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
Article
  • Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That
    • 27 May 2025
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
Social

Would you follow us ?

Contents
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
  • Adrian Gottschalk: Making a Difference for His Fellow Human Beings
    • 10 May 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.